Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

Also called NCT01970501

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 267 participants (enrolled count) (from the registry)
Sponsor
  • Medtronic Registry lists this organization as a collaborator
Registry
  • NCT NCT01970501
Other papers using this trial's data
  • Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype Circulation. Arrhythmia and electrophysiology, 2021-08 DOI, PubMed 34270905

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Hungary, Netherlands, Poland, Serbia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01970501. Randomized; quadruple masking; primary purpose treatment. Start 2014-04 (registry gives no type); primary completion 2017-12-28 (actual). Results posted on 2022-09-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Acronym
GENETIC-AF
Condition
Current or Recent History of Atrial Fibrillation
Intervention (Drug)
bucindolol hydrochloride
Intervention (Drug)
metoprolol succinate
Intervention (Other)
Placebo oral capsule
Lead sponsor
ARCA Biopharma, Inc. (class: industry)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct01970501
Content hash
d943c71a81c962078c01e9ee2a1ccdd32e9580ce0d8f506b566cc3dcb50ad886